To investigate the effectiveness of intravitreal bevacizumab injection in the treatment of Aggressive Posterior Retinopathy of Prematurity.

. In this prospective interventional case series, infants referred to Rasool Akram Hospital during Sep 2010- 2012 examined for presence of APROP and were treated by an intravitreal bevacizumab injection. Second injection was done if there was not a good clinical response. Laser photocoagulation applied if there was no response after the second injection or if the disease recurred. Patients were examined until complete retinal vascularization or complete regression.

171 eyes (90 patients) included in the study. 2 eyes missed follow up. From the 169 eyes, one injection induced disease regression in 143 eyes (84.61%), of whom 8 eyes (5.59%) experienced recurrence. In 26 eyes (15.38%) second injection was indicated, of whom 16 eyes (61.53%) experienced disease regression, and laser photocoagulation was required in 10 eyes (38.47%). Major ocular complications were tractional retinal detachment in one eye (0.59%) and strabismus at age 6 month in 5 patients (5.68%).

Intravitreal bevacizumab injection seems to be an effective method to treat APROP patients. Second injection is a good method to induce disease regression. Laser therapy is beneficial in patients without good response to Avastin injection or disease recurrence.